PureTech Health Plc (PRTC) Appoints Robert J. Hombach to its Board

PureTech Health plc (Nasdaq: PRTC), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (“Seaport”) a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert “Bob” J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin, where he also chairs the Audit Committee, and Henry Schein, a member of the S&P 500® index.

The full text of the announcement from Seaport is as follows:

Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience

You May Also Be Interested In

• Chemours reaches $450M settlement over PFAS pollution at four sites
• GraniteShares 2x Long PLTR Daily ETF (PTIR) call put ratio 5.7 calls to 1 put with a focus on July 10 calls
• Chemours to pay $112.5M to settle EPA PFAS claims